P&C Industry Claims Severity: Trends, Drivers and Mitigators

January 25, 2022

Claim severity has always been top of mind for the P&C industry. While the pandemic has certainly had an impact on claims costs, there are several drivers behind claim severity trends varying by market. While it is important to note what is behind claims costs, it is equally important to understand how to mitigate severity and control costs.

Is the Supply Chain Creating Critical Drug Shortages?

December 29, 2021

With the country well into the holiday season, issues with supply chains have made their way into pharmacies across the nation. Recently, the Food and Drug Administration (FDA) showed that there are about 111 drugs on backorder. These include medications for heart conditions, antibiotics, and cancer drugs. Currently, there are no medications on the list that represent a large volume of active prescriptions for workers’ compensation.

Release of Generic Medications for Workers' Comp in 2022

November 15, 2021

Next year twenty-eight drugs relevant to workers’ compensation are expected to become available as generics. These formulations will be made available once the original drug manufacturer’s brand name period of exclusivity has expired.

FDA Approves Combination NSAID/Opioid Seglentis

October 22, 2021

On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).

FDA Approves Combination NSAID/Opioid Seglentis

October 21, 2021

On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA). Seglentis contains tramadol, a short-acting opioid, and celecoxib, a non-steroidal anti-inflammatory drug (NSAID), and is indicated for adults in the management of acute pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Opioid Reduction Success

September 29, 2021